Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (42)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Upadhyaya, P.
Right arrow Articles by Hecht, S. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Upadhyaya, P.
Right arrow Articles by Hecht, S. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 20, No. 8, 1577-1582, August 1999
© 1999 Oxford University Press

Carcinogenesis

Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse

Pramod Upadhyaya, Patrick M.J. Kenney, J. Bradley Hochalter, Mingyao Wang and Stephen S. Hecht1

University of Minnesota Cancer Center, Box 806 Mayo, 420 Delaware Street SE, Minneapolis, MN 55455, USA

4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a major metabolite of the tobacco-specific pulmonary carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), has a chiral center but the tumorigenicity of the NNAL enantiomers has not been previously examined. In this study, we assessed the relative tumorigenic activities in the A/J mouse of NNK, racemic NNAL, (R)-NNAL, (S)-NNAL and several NNAL metabolites, including [4-(methylnitrosamino)-1-(3-pyridyl)but-(S)-1-yl] ß-O-D-gluco-siduronic acid [(S)-NNAL-Gluc], 4-(methylnitrosamino)-1-(3-pyridyl N-oxide)-1-butanol, 5-(3-pyridyl)-2-hydroxytetrahydrofuran, 4-(3-pyridyl)butane-1,4-diol and 2-(3-pyridyl) tetrahydrofuran. We also quantified urinary metabolites of racemic NNAL and its enantiomers and investigated their metabolism with A/J mouse liver and lung microsomes. Groups of female A/J mice were given a single i.p. injection of 20 µmol of each compound and killed 16 weeks later. Based on lung tumor multiplicity, (R)-NNAL (25.6 ± 7.5 lung tumors/mouse) was as tumorigenic as NNK (25.3 ± 9.8) and significantly more tumorigenic than racemic NNAL (12.1 ± 5.6) or (S)-NNAL (8.2 ± 3.3) (P < 0.0001). None of the NNAL metabolites was tumorigenic. The major urinary metabolites of racemic NNAL and the NNAL enantiomers were 4-hydroxy-4-(3-pyridyl)butanoic acid (hydroxy acid), NNAL-N-oxide and NNAL-Gluc, in addition to unchanged NNAL. Treatment with (R)-NNAL or (S)-NNAL gave predominantly (R)-hydroxy acid or (S)-hydroxy acid, respectively, as urinary metabolites. While treatment of mice with racemic or (S)-NNAL resulted in urinary excretion of (S)-NNAL-Gluc, treatment with (R)-NNAL gave both (R)-NNAL-Gluc and (S)-NNAL-Gluc in urine, apparently through the metabolic intermediacy of NNK. (S)-NNAL appeared to be a better substrate for glucuronidation than (R)-NNAL in the A/J mouse. Mouse liver and lung microsomes converted NNAL to products of {alpha}-hydroxylation, to NNAL-N-oxide, to adenosine dinucleotide phosphate adducts and to NNK. In lung microsomes, metabolic activation by {alpha}-hydroxylation of (R)-NNAL was significantly greater than that of (S)-NNAL. The results of this study provide a metabolic basis for the higher tumorigenicity of (R)-NNAL than (S)-NNAL in A/J mouse lung, namely preferential metabolic activation of (R)-NNAL in lung and preferential glucuronidation of (S)-NNAL.

Abbreviations: diol, 4-(3-pyridyl)butane-1,4-diol; hydroxy acid, 4-hydroxy-4-(3-pyridyl)butanoic acid; lactol, 5-(3-pyridyl)-2-hydroxytetrahydrofuran; LC-MS/MS, liquid chromatography–tandem mass spectrometry; MMPB, methyl 4-[{alpha}-methylbenzylcarbamoyl]-4-(3-pyridyl)butanoate; NNAL, 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanol; NNAL(ADP)+, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol adenosine dinucleotide phosphate; NNAL-Gluc, [4-(methylnitrosamino)-1-(3-pyridyl)but-(S)-1-yl] ß-O-D-glucosiduronic acid; NNAL-N-oxide, 4-(methylnitrosamino)-1-(3-pyridyl N-oxide)-1-butanol; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNK-N-oxide, 4-(methylnitrosamino)-1-(3-pyridyl N-oxide)-1-butanone; pyridyl-THF, 5-(3-pyridyl)tetrahydrofuran; UDPGA, uridine 5'-diphosphoglucoronic acid

1 To whom correspondence should be addressed Email: hecht002{at}tc.umn.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
G. Chen, R. W. Dellinger, D. Sun, T. E. Spratt, and P. Lazarus
Glucuronidation of Tobacco-Specific Nitrosamines by UGT2B10
Drug Metab. Dispos., May 1, 2008; 36(5): 824 - 830.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Chen, A. S. Blevins-Primeau, R. W. Dellinger, J. E. Muscat, and P. Lazarus
Glucuronidation of Nicotine and Cotinine by UGT2B10: Loss of Function by the UGT2B10 Codon 67 (Asp>Tyr) Polymorphism
Cancer Res., October 1, 2007; 67(19): 9024 - 9029.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Weng, C. Fang, R. J. Turesky, M. Behr, L. S. Kaminsky, and X. Ding
Determination of the Role of Target Tissue Metabolism in Lung Carcinogenesis Using Conditional Cytochrome P450 Reductase-Null Mice
Cancer Res., August 15, 2007; 67(16): 7825 - 7832.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. J. Gallagher, J. E. Muscat, A. N. Hicks, Y. Zheng, A.-M. Dyer, G. A. Chase, J. Richie, and P. Lazarus
The UDP-Glucuronosyltransferase 2B17 Gene Deletion Polymorphism: Sex-Specific Association with Urinary 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Glucuronidation Phenotype and Risk for Lung Cancer
Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 823 - 828.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. E. Murphy, C. A. Link, J. Jensen, C. Le, S. S. Puumala, S. S. Hecht, S. G. Carmella, L. Losey, and D. K. Hatsukami
A Comparison of Urinary Biomarkers of Tobacco and Carcinogen Exposure in Smokers
Cancer Epidemiol. Biomarkers Prev., October 1, 2004; 13(10): 1617 - 1623.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
U. Breyer-Pfaff, H.-J. Martin, M. Ernst, and E. Maser
ENANTIOSELECTIVITY OF CARBONYL REDUCTION OF 4-METHYLNITROSAMINO-1-(3-PYRIDYL)-1-BUTANONE BY TISSUE FRACTIONS FROM HUMAN AND RAT AND BY ENZYMES ISOLATED FROM HUMAN LIVER
Drug Metab. Dispos., September 1, 2004; 32(9): 915 - 922.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. L. Zimmerman, Z. Wu, P. Upadhyaya, and S. S. Hecht
Stereoselective metabolism and tissue retention in rats of the individual enantiomers of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), metabolites of the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
Carcinogenesis, July 1, 2004; 25(7): 1237 - 1242.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. G. Carmella, S. Han, A. Fristad, Y. Yang, and S. S. Hecht
Analysis of Total 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol (NNAL) in Human Urine
Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1257 - 1261.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
S. S. Hecht
Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer
Carcinogenesis, June 1, 2002; 23(6): 907 - 922.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. S. Hecht, S. G. Carmella, M. Ye, K.-a. Le, J. A. Jensen, C. L. Zimmerman, and D. K. Hatsukami
Quantitation of Metabolites of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone after Cessation of Smokeless Tobacco Use
Cancer Res., January 1, 2002; 62(1): 129 - 134.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Z. Wu, P. Upadhyaya, S. G. Carmella, S. S. Hecht, and C. L. Zimmerman
Disposition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in bile duct-cannulated rats: Stereoselective metabolism and tissue distribution
Carcinogenesis, January 1, 2002; 23(1): 171 - 179.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
B. Prokopczyk, N. Trushin, J. Leszczynska, S. E. Waggoner, and K. El-Bayoumy
Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via {{alpha}}-hydroxylation and carbonyl reduction pathways
Carcinogenesis, January 1, 2001; 22(1): 107 - 114.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
P. Upadhyaya, S. G. Carmella, F.P. Guengerich, and S. S. Hecht
Formation and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers in vitro in mouse, rat and human tissues
Carcinogenesis, June 1, 2000; 21(6): 1233 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. S. Hecht, T. E. Spratt, and N. Trushin
Absolute configuration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol formed metabolically from 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
Carcinogenesis, April 1, 2000; 21(4): 850 - 850.
[Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. S. Hecht, N. Trushin, S. K. Chhabra, L. M. Anderson, and P. V. Nerurkar
Short Communication: Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone by Cultured Monkey Lung Explants
Drug Metab. Dispos., January 1, 2000; 28(1): 5 - 9.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
E. M. Leslie, K.-i. Ito, P. Upadhyaya, S. S. Hecht, R. G. Deeley, and S. P. C. Cole
Transport of the beta -O-Glucuronide Conjugate of the Tobacco-specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the Multidrug Resistance Protein 1 (MRP1). REQUIREMENT FOR GLUTATHIONE OR A NON-SULFUR-CONTAINING ANALOG
J. Biol. Chem., July 20, 2001; 276(30): 27846 - 27854.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.